Solitary osseous plasmacytoma

Summary

Solitary osseous plasmacytoma (MONDO:0002755) is a disease and 11 clinical trials. Top therapeutic interventions include foscarnet, beclomethasone dipropionate, and ganciclovir. A subtype of plasmacytoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	solitary osseous plasmacytoma
Mondo ID	MONDO:0002755
DOID	DOID:3722
NCIT	C7812
SNOMED CT	426336007
UMLS	C0272256
MedGen	75777
GARD	0023234
Is cancer (heuristic)	no

Also known as: isolated plasmacytoma of bone · solitary plasmacytoma of bone · SPB

Disease family

This is a subtype of plasmacytoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › neoplasm of mature B-cells › plasma cell neoplasm › plasmacytoma › solitary osseous plasmacytoma

Related subtypes (4): extramedullary plasmacytoma, solitary plasmacytoma of chest wall, primary plasmacytoma of the bone, extramedullary soft tissue plasmacytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	4
PHASE2	3
Not specified	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02516423	PHASE3	UNKNOWN	Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
NCT07115667	PHASE2	RECRUITING	Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
NCT00489203	PHASE2	COMPLETED	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
NCT01849783	PHASE2	COMPLETED	Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
NCT00025415	PHASE1	COMPLETED	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
NCT00890747	PHASE1	COMPLETED	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
NCT01588015	PHASE1	COMPLETED	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
NCT03196401	PHASE1	WITHDRAWN	A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma
NCT01199562	Not specified	ACTIVE_NOT_RECRUITING	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
NCT00112593	Not specified	COMPLETED	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
NCT01053494	Not specified	COMPLETED	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FOSCARNET	4	4
BECLOMETHASONE DIPROPIONATE	4	1
GANCICLOVIR	4	1
LENALIDOMIDE	4	1
VALGANCICLOVIR	4	1
IXAZOMIB	3	1
CHEMBL1319520	0	1